Halozyme Therapeutics and Baxter announce collaboration for development of Subcutaneous GAMMAGARD LIQUID Administration using Enhanze (HALO) 9.07 : BAX and HALO announce they have entered into an agreement to apply Halozyme'sproprietary Enhanze Technology to the development of a subcutaneous route ofadministration for Baxter's GAMMAGARD LIQUID 10%. For patients using GAMMAGARD LIQUID 10% -- currently administered intravenously -- subcutaneousadministration with Enhanze Technology may increase overall convenience andimprove the dispersion of the therapy. Under the terms of the agreement, Baxter will provide Halozyme an initialupfront payment of $10 million. Pending successful completion of a series of regulatory and sales milestones, Baxter may make further milestone payments totaling $37 million to Halozyme. Baxter also will assume development, manufacturing, clinical, regulatory, sales and marketing costs.
Caspermick
"TOUGH TIMES NEVER LAST BUT TOUGH PEOPLE DO."
God Bless America
In Gambling,,,Playing Card Games. Ya Never Know What The Next Hand Will Look Like.
Ten Bagger Potential Stock
